Wacker, XL-protein produce PASylated biopharmaceuticals

Wacker, XL-protein to produce PASylated biopharmaceuticals

9:44 AM, 5th November 2012
Wacker, XL-protein to produce PASylated biopharmaceuticals

MUNICH/FREISING, GERMANY/JENA, US: Wacker Biotech and XL-protein GmbH are to collaborate more intensely on the production of PASylated therapeutic proteins. WACKER and its customers will gain access to XL-protein’s PASylation platform. The PASylation technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. In a recent feasibility study, PASylated human growth hormone was successfully produced in high yields using WACKER’s E. coli-based ESETEC technology.

In a feasibility study, Wacker Biotech and XL-protein tested WACKER’s patented ESETEC technology for the production of large-sized PASylated therapeutic proteins. The study showed that ESETEC produced a PASylated human growth hormone – correctly folded and fully functional – in high yields (3 to 4 g/l). Moreover, WACKER successfully used its secretion technology to develop an E. coli cell line for manufacturing the PASylated hormone. The production process is easy to implement on an industrial scale.

“Following the successful feasibility study, we are very much looking forward to intensifying our collaboration with XL-protein. More and more pharmaceutical companies are looking for efficient ways of prolonging the therapeutic effect of biologics. With this cooperation agreement with XL-protein, we can now offer our customers feasibility studies for the production of PASylated variants of their therapeutic lead candidates. Thanks to our innovative ESETEC technology, we can supply research quantities of PASylated active ingredients for pre-clinical studies within a couple of weeks,” said Dr Thomas Maier, Managing Director, Wacker Biotech GmbH.

© WOC News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Teijin starts full scale operations in Thailand

TOKYO, JAPAN: Teijin Limited announced that Teijin Thailand Limited in the Bang Pa-in Industrial Estate of Thailand’s Ayutthaya Province, which ...

Read more
Israel rejects Potash Corporation’s attempt to buy ICL

TEL AVIV, ISRAEL: The Israeli government has moved to block Potash Corporation of Canada’s attempt to buy rival fertiliser group Israel Chemical ...

Read more
ExxonMobil appoints Ursula M Burns to its board

IRVING, US: Exxon Mobil Corporation elected Ursula M Burns to its board of directors, effective November 27, 2012. Burns is Chairman and Chief Executi ...

Read more
Nippon Shokubai considers restarting Tennessee, US plant

OSAKA, JAPAN: Japanese chemical maker Nippon Shokubai is considering restarting its closed plant for water-absorbing resin in the United States as the ...

Read more
Fluor bags Shell downstream projects in Europe, Africa and Middle East

IRVING, US: Fluor Corporation is awarded a 5-year enterprise framework agreement for engineering and project management services by Shell for its down ...

Read more
BASF opens new dispersions plant in Huizhou, China

HUIZHOU, CHINA: BASF inaugurated its new dispersions plant in Daya Bay Petrochemical Industrial Park in Huizhou, China. The new plant will produce sty ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X